|MDACC Study No:||RTOG0929 (clinicaltrials.gov NCT No: NCT01026493)|
|Title:||A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma|
|Principal Investigator:||John DeGroot|
|Treatment Agent:||ABT-888; Temozolomide|
|Study Description:||The goal of Phase I of this clinical research study is to find the highest |
tolerable dose of the combination of ABT-888 and temozolomide that can be given
to patients with glioblastoma.
The goal of Phase II of this clinical research study is to learn if the
combination of temozolomide and ABT-888 can help to control glioblastoma. Two
(2) different dose schedules of the study drug combination will also be
The safety of these drug combinations will also be studied in both phases.